FI3010962T4 - Sigmoidaalisen vapautumisprofiilin omaavien polylaktidi-polyglykolidimikrohiukkasten valmistus - Google Patents

Sigmoidaalisen vapautumisprofiilin omaavien polylaktidi-polyglykolidimikrohiukkasten valmistus Download PDF

Info

Publication number
FI3010962T4
FI3010962T4 FIEP14733524.4T FI14733524T FI3010962T4 FI 3010962 T4 FI3010962 T4 FI 3010962T4 FI 14733524 T FI14733524 T FI 14733524T FI 3010962 T4 FI3010962 T4 FI 3010962T4
Authority
FI
Finland
Prior art keywords
microparticles
phase
organic solvent
polymer
risperidone
Prior art date
Application number
FIEP14733524.4T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Evangelos Karavas
Efthymios Koutris
Sotiria Haitidou
Theofanis Mantourlias
Georgia Papanikolaou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FI3010962T4 publication Critical patent/FI3010962T4/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02Making microcapsules or microballoons
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/12Powdering or granulating
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/12Powdering or granulating
    • C08J3/14Powdering or granulating by precipitation from solutions
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2300/00Characterised by the use of unspecified polymers
    • C08J2300/16Biodegradable polymers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2367/00Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
    • C08J2367/04Polyesters derived from hydroxy carboxylic acids, e.g. lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FIEP14733524.4T 2013-06-20 2014-06-18 Sigmoidaalisen vapautumisprofiilin omaavien polylaktidi-polyglykolidimikrohiukkasten valmistus FI3010962T4 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2013001821 2013-06-20
PCT/EP2014/001652 WO2014202214A1 (en) 2013-06-20 2014-06-18 Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile

Publications (1)

Publication Number Publication Date
FI3010962T4 true FI3010962T4 (fi) 2023-05-04

Family

ID=51022802

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP14733524.4T FI3010962T4 (fi) 2013-06-20 2014-06-18 Sigmoidaalisen vapautumisprofiilin omaavien polylaktidi-polyglykolidimikrohiukkasten valmistus

Country Status (15)

Country Link
US (1) US9943484B2 (https=)
JP (1) JP6464154B2 (https=)
CN (1) CN105308101B (https=)
AU (1) AU2014283692B2 (https=)
CA (1) CA2916301C (https=)
DK (1) DK3010962T4 (https=)
ES (1) ES2640486T5 (https=)
FI (1) FI3010962T4 (https=)
HU (1) HUE036141T2 (https=)
LT (1) LT3010962T (https=)
PT (1) PT3010962T (https=)
RU (1) RU2658004C2 (https=)
SA (1) SA515370296B1 (https=)
WO (1) WO2014202214A1 (https=)
ZA (1) ZA201509354B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796137A (zh) * 2014-07-30 2022-07-29 默克专利股份有限公司 包含微晶纤维素的可直接压制的组合物
JP2016102093A (ja) * 2014-11-28 2016-06-02 ニプロ株式会社 塩基性の求核化合物を含有するマイクロカプセルの製造方法
EP3352735B1 (en) 2015-09-21 2023-08-30 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulations
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
KR102047983B1 (ko) * 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법
GR1009870B (el) * 2019-07-09 2020-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα ατυπο αντιψυχωσικο φαρμακο και μεθοδος παρασκευης αυτου
WO2021134623A1 (zh) * 2019-12-31 2021-07-08 广州帝奇医药技术有限公司 一种叔胺药物组合物及其产业化批量制备方法
EP4125823A1 (en) 2020-03-30 2023-02-08 Biological E Limited Risperidone microspheres, process for their prepartion and uses thereof
KR102259589B1 (ko) * 2020-11-30 2021-06-02 (주)인벤티지랩 미소구체 제조 시스템 및 미소구체 제조 방법
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
CA3210098A1 (en) * 2021-02-24 2022-09-01 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
JP2024529009A (ja) 2021-07-06 2024-08-01 マーク・ヘースルトン セロトニン再取り込み阻害剤離脱症候群の治療
GR1010327B (el) * 2021-10-06 2022-10-17 Φαρματεν Α.Β.Ε.Ε., Παρατεταμενης αποδεσμευσης ενεσιμο φαρμακευτικο σκευασμα λεβοθυροξινης και μεθοδος παρασκευης αυτου
WO2025135778A1 (ko) * 2023-12-18 2025-06-26 주식회사 포스테라헬스사이언스 약물의 특성에 따른 활성형 미립자의 제조 방법, 이의 제조 방법으로 제조된 활성형 미립자 및 상기 활성형 미립자를 이용한 약물을 포함하는 장기 지속 제형의 제조 방법
WO2025207396A1 (en) * 2024-03-27 2025-10-02 Avidence Therapeutics, Inc. Microsphere-based injectable rofecoxib formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478564A (en) * 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
US5288496A (en) 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
WO1997026869A1 (en) * 1996-01-24 1997-07-31 United States Government Represented By The Secretary Of The Army Novel 'burst-free' sustained release poly-(lactide/glycolide) microspheres
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US7690026B2 (en) * 2005-08-22 2010-03-30 Microsoft Corporation Distributed single sign-on service

Also Published As

Publication number Publication date
US9943484B2 (en) 2018-04-17
ES2640486T5 (es) 2023-04-28
CN105308101B (zh) 2018-10-23
CA2916301C (en) 2020-01-07
JP2017507895A (ja) 2017-03-23
PT3010962T (pt) 2017-09-05
DK3010962T4 (da) 2023-04-17
AU2014283692A1 (en) 2016-01-21
RU2658004C2 (ru) 2018-06-19
RU2016101418A (ru) 2017-07-25
CA2916301A1 (en) 2014-12-24
CN105308101A (zh) 2016-02-03
DK3010962T3 (en) 2017-10-23
JP6464154B2 (ja) 2019-02-06
ES2640486T3 (es) 2017-11-03
WO2014202214A1 (en) 2014-12-24
SA515370296B1 (ar) 2017-10-12
US20160143851A1 (en) 2016-05-26
ZA201509354B (en) 2017-07-26
HUE036141T2 (hu) 2018-06-28
AU2014283692B2 (en) 2017-04-27
LT3010962T (lt) 2017-09-25

Similar Documents

Publication Publication Date Title
FI3010962T4 (fi) Sigmoidaalisen vapautumisprofiilin omaavien polylaktidi-polyglykolidimikrohiukkasten valmistus
JP2017507895A5 (https=)
CN103785335B (zh) 一种无机相变微胶囊的制备方法及无机相变微胶囊
Zhang et al. Schizophyllan: A review on its structure, properties, bioactivities and recent developments
ES2573710T3 (es) Circulación de componentes durante la homogeneización y de microfluidización de emulsiones
ES2722748T3 (es) Procedimiento para la producción de látex por emulsificación mediante fusión
BR112016012902A2 (pt) Aparelho, método e sistema para um mecanismo de configuração rápida
MX362709B (es) Microesferas de buprenorfina de fuerte carga de medicamento y su método de fabricación.
BR112017010322A2 (pt) composição, método de tratamento de formação subterrânea, e, uso no tratamento de formação subterrânea
JP2016507478A5 (https=)
MX2016007871A (es) Espuma polimerica.
BR112016028385A2 (pt) método e sistema para reduzir uma concentração de solvente em uma pluralidade de micropartículas, método para preparar uma pluralidade de microesferas biodegradáveis com um agente medicinalmente ativo, e, composição.
BR112016013316A8 (pt) método para a produção de furfural e uso de ácido metanossulfônico
MX2015009701A (es) Proceso de obtencion de nonoparticulas biopolimericas conteniendo aceite y extractos de azadirachta indica a, juss (neem), nanoparticulas biopolimericas y microparticulas en polvo.
BR112017007244A2 (pt) ?composição de indicador químico, indicador de processo de autoclave e método para a preparação do indicador de processo de autoclave?
WO2013040331A3 (en) Method for preparing personal care composition comprising surfactant system and high melting point fatty compound
BR112017006347A2 (pt) método de tratamento de uma porção de um poço, sistema, e, fluido de tratamento de poço.
RU2017141919A (ru) Способ получения пузырьков с трансмембранным градиентом рн
ES2625873T3 (es) Método de preparación de micropartículas biodegradables que contienen fármacos
Sun et al. Microstructure, thermal properties and rheological behavior of PLA/PCL blends for melt-blown nonwovens
HRP20171402T4 (hr) Priprava polilaktidno-poliglikolidnih mikročestica sa sigmoidnim profilom oslobađanja
EP2415356A3 (de) Mikroverkapseltes Nahrungssubstrat zur Zucht von räuberischen Spinnentieren
RU2016101691A (ru) Способ получения нанокапсул резвератрола в конжаковой камеди
WO2015147705A3 (ru) Способ приготовления стерильной наноэмульсии перфторорганических соединений
TH152488A (th) อิมัลชั่นชนิด w/o/w ที่มีความเสถียรตามเวลา และ วิธีการสำหรับการผลิตสารนั้น